Sarepta Therapeutics (SRPT) Current Deferred Revenue (2010 - 2026)

Sarepta Therapeutics' Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $116.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 158.67% year-over-year to $116.0 million; the TTM figure through Mar 2026 stood at $116.0 million (up 158.67% YoY), while the FY2025 annual figure was $443.4 million, up 240.4% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $116.0 million, down from $443.4 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $485.4 million in Q3 2025, with the low at $22.5 million in Q3 2023.
• The 5-year median for Current Deferred Revenue is $89.2 million (2022), against an average of $148.2 million.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue sank 74.79% in 2023, then soared 464.6% in 2024.
• Sarepta Therapeutics' Current Deferred Revenue stood at $89.2 million in 2022, then plunged by 43.51% to $50.4 million in 2023, then surged by 158.36% to $130.3 million in 2024, then surged by 240.4% to $443.4 million in 2025, then sank by 73.83% to $116.0 million in 2026.
• Business Quant data shows SRPT's Current Deferred Revenue at $116.0 million in Q1 2026, $443.4 million in Q4 2025, and $485.4 million in Q3 2025.